Notícias Actinium Pharmaceuticals Inc - ATNM | Ações American Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
AMEX
Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals Inc (ATNM) Notícias

Actinium Pharmaceuticals Inc (ATNM)

1,45

-0,02

(-1,36%)

Fechado 23 Novembro 6:00PM

Atrasado por 15 minutos

1,46

0,01

(0,69%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form ARS - Annual Report to Security Holders

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Actinium Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições